Publicacións nas que colabora con Nuria Martínez Cibrián (7)

2024

  1. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

    Blood, Vol. 144, Núm. 3, pp. 334-338

  2. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

    Leukemia

  3. Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy

    HemaSphere, Vol. 8, Núm. 5

2023

  1. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

    Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437

  2. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  3. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

2021

  1. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

    Cancer Medicine, Vol. 10, Núm. 10, pp. 3214-3223